<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">kurskvest</journal-id><journal-title-group><journal-title xml:lang="ru">Человек и его здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Humans and their health</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1998-5746</issn><issn pub-type="epub">1998-5754</issn><publisher><publisher-name>Kursk State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21626/vestnik/2022-1/04</article-id><article-id custom-type="elpub" pub-id-type="custom">kurskvest-992</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Применение комплексных лекарственных препаратов для лечения пациентов с болью в спине</article-title><trans-title-group xml:lang="en"><trans-title>Use of complex medications to treat patients with back pain</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9781-6169</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шутеева</surname><given-names>Елена Юрьевна</given-names></name><name name-style="western" xml:lang="en"><surname>Shuteeva</surname><given-names>Elena Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>студент, КГМУ, г. Курск</p></bio><bio xml:lang="en"><p>student, KSMU, Kursk, Russian Federation</p></bio><email xlink:type="simple">lendlendleda@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5163-575X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крапива</surname><given-names>Анна Борисовна</given-names></name><name name-style="western" xml:lang="en"><surname>Krapiva</surname><given-names>Anna B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>студент, КГМУ, г. Курск</p></bio><bio xml:lang="en"><p>student, KSMU, Kursk, Russian Federation</p></bio><email xlink:type="simple">anny1999.10@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4009-2638</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шутеева</surname><given-names>Татьяна Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Shuteeva</surname><given-names>Tatiana V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, доцент, и.о. зав. кафедрой неврологии и нейрохирургии, КГМУ, г. Курск</p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), Associate Professor, acting Head of the Department of Neurology and Neurosurgery, KSMU, Kursk, Russian Federation</p></bio><email xlink:type="simple">shuteeva@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Курский государственный медицинский университет (КГМУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kursk State Medical University (KSMU)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>29</day><month>03</month><year>2022</year></pub-date><volume>25</volume><issue>1</issue><fpage>28</fpage><lpage>34</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шутеева Е.Ю., Крапива А.Б., Шутеева Т.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Шутеева Е.Ю., Крапива А.Б., Шутеева Т.В.</copyright-holder><copyright-holder xml:lang="en">Shuteeva E.Y., Krapiva A.B., Shuteeva T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.kursk-vestnik.ru/jour/article/view/992">https://www.kursk-vestnik.ru/jour/article/view/992</self-uri><abstract><p>Цель исследования: оценка динамики болевых показателей и различных характеристик качества жизни у пациентов болью в спине при использовании однокурсового лечебного комплекса с применением клодифена нейро. Материалы и методы. В исследование были включены мужчины и женщины в возрасте от 44 до 52 лет с жалобами на боли в пояснице, обусловленные обострением хронической дорсалгии. Основная группа включала 30 пациентов (14 мужчин и 16 женщин). Группа контроля была представлена 24 пациентами (12 мужчин и 12 женщин). Группы были сопоставимы по степени выраженности симптоматики, стажу заболевания. Все пациенты получали миорелаксанты и гастропротекторы соответствующих фармакологических групп, пациенты основной группы получали клодифен нейро по 1 касуле два раза в день в течение 2-х недель, пациенты группы контроля - диклофенак в таблетках (кишечнорастворимая форма) по 50 мг два раза в день. Оценивалась эффективность терапии с помощью шкалы ВАШ и опросника Освестри. Оценка состояния пациентов обеих групп проводилась до начала исследования, после окончания лечения (через 14 дней) и через 2 месяца после окончания терапии. Результаты. Проведенное исследование эффективности применения клодифена нейро показало, что у больных с хронической болью в спине препарат благоприятствовал уменьшению болевого синдрома, увеличению подвижности позвоночника, функционального потенциала пациентов. Заключение. Лечение клодифеном нейро на протяжении 14 дней (по 1 капсуле внутрь 2 раза в день) в составе комплексной терапии способствовало устойчивому уменьшению болевого синдрома в исследуемой группе пациентов с хронической болью в спине. Обезболивающий эффект сохранялся в течение 2 месяцев после окончания терапии. Клодифен нейро может быть рекомендован в качестве политропного средства в составе комплексной терапии хронической боли в спине.</p></abstract><trans-abstract xml:lang="en"><p>Purpose of the study: to assess the dynamics of pain indicators and various characteristics of the quality of life in patients with back pain when using a one-course treatment complex with the use of Clodifen Neuro. Materials and methods. The study included men and women aged 44 to 52 years with complaints of lower back pain caused by exacerbation of chronic dorsalgia. The main group included 30 patients (14 men and 16 women). The control group consisted of 24 patients (12 men and 12 women). The groups were comparable in terms of the severity of symptoms and the length of the disease. All patients received muscle relaxants and gastroprotectors of the corresponding pharmacological groups, patients in the main group received Clodifen Neuro 1 capsule twice a day for 2 weeks, patients in the control group received diclofenac tablets (enteric form) 50 mg twice a day. The effectiveness of therapy was assessed using the VAS scale and the Oswestry questionnaire. Assessment of the condition of patients in both groups was carried out before the start of the study, after the end of treatment (after 14 days) and 2 months after the end of therapy. Results. The study of the effectiveness of the use of Clodifen Neuro showed that in patients with chronic back pain, the drug favored a decrease in pain syndrome, an increase in the mobility of the spine, and the functional potential of patients. Conclusion. Treatment with Clodifen Neuro for 14 days (1 capsule orally 2 times a day) as a part of complex therapy contributed to a steady reduction in pain in the study group of patients with chronic back pain. The analgesic effect persisted for 2 months after the end of therapy. Clodifen Neuro can be recommended as a polytropic agent in the complex therapy of chronic back pain.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>боль в спине</kwd><kwd>диклофенак</kwd><kwd>клодифен нейро</kwd></kwd-group><kwd-group xml:lang="en"><kwd>back pain</kwd><kwd>diclofenac</kwd><kwd>Clodifen Neuro</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vertkin A.L., Karateev A.E., Kukushkin M.L. i dr. Curation of patients with back pain for physicians and general practitioners (clinical recommendations). Terapiya. 2018;2(20):24-32 (in Russ.)</mixed-citation><mixed-citation xml:lang="en">Vertkin A.L., Karateev A.E., Kukushkin M.L. i dr. Curation of patients with back pain for physicians and general practitioners (clinical recommendations). Terapiya. 2018;2(20):24-32 (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tagliaferri S.D., Miller C.T., Owen P.J., Mitchell U.H., Brisby H., Fitzgibbon B., Masse-Alarie H., Van Oosterwijck J. et al. Domains of Chronic Low Back Pain and Assessing Treatment Effectiveness: A Clinical Perspective. Pain Pract. 2020;20(2):211-225. DOI: 10.1111/papr.12846</mixed-citation><mixed-citation xml:lang="en">Tagliaferri S.D., Miller C.T., Owen P.J., Mitchell U.H., Brisby H., Fitzgibbon B., Masse-Alarie H., Van Oosterwijck J. et al. Domains of Chronic Low Back Pain and Assessing Treatment Effectiveness: A Clinical Perspective. Pain Pract. 2020;20(2):211-225. DOI: 10.1111/papr.12846</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Shuteeva T.V. Effectiveness of the drug Drastop in the treatment of chronic back pain. Effektivnaya farmakoterapiya. 2019;15(39):16-20 (in Russ.). DOI: 10.33978/2307-3586-2019-15-39-16-20</mixed-citation><mixed-citation xml:lang="en">Shuteeva T.V. Effectiveness of the drug Drastop in the treatment of chronic back pain. Effektivnaya farmakoterapiya. 2019;15(39):16-20 (in Russ.). DOI: 10.33978/2307-3586-2019-15-39-16-20</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dionne C.E., Dunn K.M., Croft P.R., Nachemson A.L., Buchbinder R., Walker B.F., Wyatt M., Cassidy J.D. et al. A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine (Phila Pa 1976). 2008;33(1):95-103. DOI: 10.1097/BRS.0b013e31815e7f94</mixed-citation><mixed-citation xml:lang="en">Dionne C.E., Dunn K.M., Croft P.R., Nachemson A.L., Buchbinder R., Walker B.F., Wyatt M., Cassidy J.D. et al. A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine (Phila Pa 1976). 2008;33(1):95-103. DOI: 10.1097/BRS.0b013e31815e7f94</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yudel’son Ya.B., Rachin A.P., Belogorokhov O.O. Efficacy and safety of the drug Neurodiclovit in dorsalgia. Farmateka. 2008;20(174): 132-136 (in Russ.)</mixed-citation><mixed-citation xml:lang="en">Yudel’son Ya.B., Rachin A.P., Belogorokhov O.O. Efficacy and safety of the drug Neurodiclovit in dorsalgia. Farmateka. 2008;20(174): 132-136 (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zafar F., Qasim Y.F., Farooq M.U., Shamael I., Khan I.U., Khan D.H. The Frequency of Different Risk Factors for Lower Back Pain in a Tertiary Care Hospital. Cureus. 2018;10(8):e3183. DOI: 10.7759/cureus.3183</mixed-citation><mixed-citation xml:lang="en">Zafar F., Qasim Y.F., Farooq M.U., Shamael I., Khan I.U., Khan D.H. The Frequency of Different Risk Factors for Lower Back Pain in a Tertiary Care Hospital. Cureus. 2018;10(8):e3183. DOI: 10.7759/cureus.3183</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chou R., Deyo R., Friedly J., Skelly A., Weimer M., Fu R., Dana T., Kraegel P. et al. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7): 480-492. DOI: 10.7326/M16-2458</mixed-citation><mixed-citation xml:lang="en">Chou R., Deyo R., Friedly J., Skelly A., Weimer M., Fu R., Dana T., Kraegel P. et al. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7): 480-492. DOI: 10.7326/M16-2458</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Schuttert I., Timmerman H., Petersen K.K., McPhee M.E., Arendt-Nielsen L., Reneman M.F., Wolff A.P. The Definition, Assessment, and Prevalence of (Human Assumed) Central Sensitisation in Patients with Chronic Low Back Pain: A Systematic Review. J Clin Med. 2021;10(24):5931. DOI: 10.3390/jcm10245931</mixed-citation><mixed-citation xml:lang="en">Schuttert I., Timmerman H., Petersen K.K., McPhee M.E., Arendt-Nielsen L., Reneman M.F., Wolff A.P. The Definition, Assessment, and Prevalence of (Human Assumed) Central Sensitisation in Patients with Chronic Low Back Pain: A Systematic Review. J Clin Med. 2021;10(24):5931. DOI: 10.3390/jcm10245931</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Buchner M., Zahlten-Hinguranage A., Schiltenwolf M., Neubauer E. Therapy outcome after multidisciplinary treatment for chronic neck and chronic low back pain: a prospective clinical study in 365 patients. Scand J Rheumatol. 2006;35(5):363-367. DOI: 10.1080/03009740600759795</mixed-citation><mixed-citation xml:lang="en">Buchner M., Zahlten-Hinguranage A., Schiltenwolf M., Neubauer E. Therapy outcome after multidisciplinary treatment for chronic neck and chronic low back pain: a prospective clinical study in 365 patients. Scand J Rheumatol. 2006;35(5):363-367. DOI: 10.1080/03009740600759795</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Li J., Chen Y., Liu J., Zhang D., Liang P., Lu P., Shen J., Miao C. et al. Elevated Expression and Activity of Sodium Leak Channel Contributes to Neuronal Sensitization of Inflammatory Pain in Rats. Front Mol Neurosci. 2021;(140:723395. DOI: 10.3389/fnmol.2021.723395</mixed-citation><mixed-citation xml:lang="en">Li J., Chen Y., Liu J., Zhang D., Liang P., Lu P., Shen J., Miao C. et al. Elevated Expression and Activity of Sodium Leak Channel Contributes to Neuronal Sensitization of Inflammatory Pain in Rats. Front Mol Neurosci. 2021;(140:723395. DOI: 10.3389/fnmol.2021.723395</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Karateev A.E., Karateev D.E., Davydov O.S. Pain and inflammation. Part 2. The analgesic potential of anti-inflammatory drugs. Scientific and practical rheumatology. 2017;55(1):58-67 (in Russ.). DOI: 10.14412/1995-4484-2017-58-67</mixed-citation><mixed-citation xml:lang="en">Karateev A.E., Karateev D.E., Davydov O.S. Pain and inflammation. Part 2. The analgesic potential of anti-inflammatory drugs. Scientific and practical rheumatology. 2017;55(1):58-67 (in Russ.). DOI: 10.14412/1995-4484-2017-58-67</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dehghan M.Comparative effectiveness of B and E vitamins with diclofenac in reducing pain due to osteoarthritis of the knee. Med Arch. 2015;69(2): 103-106. DOI: 10.5455/medarh.2015.69.103-106</mixed-citation><mixed-citation xml:lang="en">Dehghan M.Comparative effectiveness of B and E vitamins with diclofenac in reducing pain due to osteoarthritis of the knee. Med Arch. 2015;69(2): 103-106. DOI: 10.5455/medarh.2015.69.103-106</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Song X.S., Huang Z.J., Song X.J. Thiamine suppresses thermal hyperalgesia, inhibits hyperexcitability, and lessens alterations of sodium currents in injured, dorsal root ganglion neurons in rats. Anesthesiology. 2009;110(2):387-400. DOI: 10.1097/ALN.0b013e3181942f1e</mixed-citation><mixed-citation xml:lang="en">Song X.S., Huang Z.J., Song X.J. Thiamine suppresses thermal hyperalgesia, inhibits hyperexcitability, and lessens alterations of sodium currents in injured, dorsal root ganglion neurons in rats. Anesthesiology. 2009;110(2):387-400. DOI: 10.1097/ALN.0b013e3181942f1e</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Menezes R.R., Godin A.M., Rodrigues F.F., Coura G.M.E., Melo I.S.F., Brito A.M.S. et al. Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund's adjuvant. Pharmacol Rep. 2017;69(5):1036-1043. DOI: 10.1016/j.pharep.2017.04.011</mixed-citation><mixed-citation xml:lang="en">Menezes R.R., Godin A.M., Rodrigues F.F., Coura G.M.E., Melo I.S.F., Brito A.M.S. et al. Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund's adjuvant. Pharmacol Rep. 2017;69(5):1036-1043. DOI: 10.1016/j.pharep.2017.04.0115</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z.B., Gan Q., Rupert R.L., Zeng Y.M., Song X.J. Thiamine, pyridoxine, cyanocobalamin and their combination inhibit thermal, but not mechanical hyperalgesia in rats with primary sensory neuron injury. Pain. 2005;114(1-2):266-277. DOI: 10.1016/j.pain.2004.12.027</mixed-citation><mixed-citation xml:lang="en">Wang Z.B., Gan Q., Rupert R.L., Zeng Y.M., Song X.J. Thiamine, pyridoxine, cyanocobalamin and their combination inhibit thermal, but not mechanical hyperalgesia in rats with primary sensory neuron injury. Pain. 2005;114(1-2):266-277. DOI: 10.1016/j.pain.2004.12.027</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
